切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2007, Vol. 01 ›› Issue (03) : 44 -47. doi: 10.3877/cma.j.issn.1674-0807.2007.03.014

实验研究

乳腺浸润性导管癌中聚集素的表达及其与Bax的关系
臧家兰1, 李春红1, 曹鸿雁1, 蔡莉1,()   
  1. 1.150040 哈尔滨,哈尔滨医科大学附属第三医院内科
  • 收稿日期:2007-04-23 出版日期:2007-06-01
  • 通信作者: 蔡莉

Study on the expression of clusterin and the relationship between clusterin and Bax in infiltrating ductal carcinoma of the breast

Jia-lan ZANG1, Chun-hong LI1, Hong-yan CAO1, Li CAI,1()   

  1. 1.The 4th Department of Internal Medicine,the 3rd Affiliated Hospital of Harbin Medical University,Harbin 150040,China
  • Received:2007-04-23 Published:2007-06-01
  • Corresponding author: Li CAI
引用本文:

臧家兰, 李春红, 曹鸿雁, 蔡莉. 乳腺浸润性导管癌中聚集素的表达及其与Bax的关系[J/OL]. 中华乳腺病杂志(电子版), 2007, 01(03): 44-47.

Jia-lan ZANG, Chun-hong LI, Hong-yan CAO, Li CAI. Study on the expression of clusterin and the relationship between clusterin and Bax in infiltrating ductal carcinoma of the breast[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2007, 01(03): 44-47.

目的

探讨聚集素(clusterin)、Bax在乳腺浸润性导管癌中的表达及意义。

方法

采用S-P免疫组化方法,检测乳腺浸润性导管癌组织中clusterin和Bax的表达状态。

结果

Clusterin在正常乳腺组织中不表达,在62.79%(27/43)的乳腺浸润性导管癌组织中阳性表达。Clusterin在乳腺浸润性导管癌组织中的表达与年龄、绝经状态无关,而与肿瘤的分化程度(r=0.3799,P=0.0266)、临床分期(r=0.3206,P=0.0356)、肿瘤大小(r=0.3671,P=0.0365)及有无淋巴结转移(r=0.5937,P=0.0005)呈正相关。Clusterin与Bax的表达呈负相关(r=-0.3273,P﹤0.05),与ER、PR的表达状态均呈负相关(r分别为-0.3038、-0.3451,P分别为0.0125、0.0236),与HER-2表达无相关性(r=0.2644,P=0.1719)。

结论

Clusterin的表达状态在乳腺癌的发生、发展中可能起着重要的作用。

Objective

To investigate the expression and significance of clusterin(a newly discovered antipoptosis protein,which is overexpressed in many cancers and plays an important role in the development of cancer)in infiltrating ductal carcinoma of the breast.

Methods

The expressions of clusterin and Bax in infiltrating ductal carcinoma of the breast were examined by immunohistochemical S-P method.

Results

The expression of clusterin was negative in normal breast tissues.The overexpression rate of clusterin in infiltrating ductal carcinoma of the breast was 62.79%(27/43).The expression level of clusterin in infiltrating ductal carcinoma of the breast was not related to age and mentopausal state,but was related positively with pathological differentiation(r=0.3799,P=0.0266),clinical stage(r=0.3206,P=0.0356)and lymph node metastasis(r=0.5937,P=0.0005).The expression level of clusterin in infitrating ductal carcinoma of the breast had a negative correlation with Bax(r=-0.3273,P﹤0.05),ER(r=-0.3038,P﹤0.05)and PR expression(r=-0.3451,P﹤0.05),and had no correlation with HER-2(r=0.2644,P﹥0.05).

Conclusion

Clusterin may play an important role in the carcinogenesis and development of infiltrating breast carcinoma.

表1 Clusterin在乳腺浸润性导管癌中的表达与临床病理因素之间的关系
[1]
Mcphersonk K,Steel C M,Dixon J M.ABC of breast diseases:breast cancer epidemiology,risk factors,and genetics.BMJ,2000,321:624-628.
[2]
Lee S,Schmitt C A.Chemotherapy response and resistance.Curr Opin Genet Dev,2003,13:90-96.
[3]
Gleave ME,Miyake H.Use of antisense oligonucleotides targeting the cytoprotective gene,clusterin,to enhance androgen and chemosensitivity in prostate cancer.World J Urol,2005,23:38-46.
[4]
Debure L,Vayssiere J L,Rincheval V,et al.Intracellular clusterin causes juxta-nclear aggregate formation and mitochondrial alteration.J Cell Sci,2003,116:3109-3121.
[5]
Caccamo A E,Scaltriti M,Caporali A,et al.Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a Mr45000 nuclear isoform of clusterin.Biochem J,2004,382(Ptl):157-168.
[6]
Trougakos I P,Gonos E S.Clusterin/apolipoprotein J in human aging and cancer.Int J Biochem Cell Biol,2002,34:1430-1448.
[7]
Redondo M,Villar E,Torres Munoz J,et al.Overexpression of clusterin in human breast carcinoma.Am J Pathol,2000,157:393-399.
[8]
Kruger S,Ola V,Fischer D,et al.Prognostic si-gnificance of clusterin immunoreactivity in breast cancer.Neoplasma,2007,54:46-50.
[9]
Criswell T,Klokov D,Beman M,et al.Repression of IR-inducible clusterin expression by the p53 tumour suppressor protein.Cancer Biol Ther,2003,2:372-380.
[10]
Zhang H,Kim J K,Edwards CA,et al.Clusterin inhibits apoptosis by interacting with activated Bax.Nat Cell Biol,2005,7:909-915.
[11]
Biroccio A,D'Angelo C,Jansen B,et al.Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.J Cell Physiol,2005,204:463-469.
[12]
So A,Sinnemann S,Huntsman D,et al.Knochdown of the cytoprotective chaperone,clusterin,chemosensitizes human breast cancer cells both in vitro and in vivo.Mol Cancer Ther,2005,4:1850-1859.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[3] 杨柳, 宋振川, 王新乐. 乳腺癌改良根治术联合背阔肌复位的临床疗效评估[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 269-273.
[4] 牛海刚, 郭文科. 三阴性乳腺癌组织中双特异性磷酸酶14与核受体相互作用蛋白1的表达及预后价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(04): 199-205.
[5] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[6] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[7] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[8] 唐丹萍, 王萍, 江孟蝶, 杨晓蓉. 自体脂肪移植在乳腺癌术后乳房重建的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 582-585.
[9] 黄程鑫, 陈莉, 刘伊楚, 王水良, 赖晓凤. OPA1 在乳腺癌组织的表达特征及在ER阳性乳腺癌细胞中的生物学功能研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 275-284.
[10] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[11] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[12] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[13] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要